|
Synonyms: ADCT-402 | ADCT402 | loncastuximab tesirine-lpyl | RB4v1.2-SG-3249 | Zynlonta®
loncastuximab tesirine is an approved drug (FDA (2021), EMA (2022))
Compound class:
Antibody
Comment: Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate that delivers the toxic payload teserine (pyrrolobenzodiazepine dimer SG3249, which acts as a DNA alkylating and cross-linking agent [4]) to CD19-expressing B cells [6]. The linker contains a valine-alanine dipeptide bridge that is specifically recognized and cleaved by cathepsin B (CTSB; which is highly expressed by tumour cells) [3,5].
|
| No information available. |
Summary of Clinical Use ![]() |
| Loncastuximab tesirine was advenced to clinical evaluation for B cell malignancies [1-2]. IT was approved by the FDA in April 2021 (via the accelerated approval route), as a therapy for previously treated relapsed or refractory large B-cell lymphoma. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | Phase 1 Interventional | ADC Therapeutics S.A. | 1 | |